The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Snyder, S. H.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Snyder, S. H.

Am J Psychiatry 1976; 133:197-202
Copyright © 1976 by American Psychiatric Association


REGULAR ARTICLES

The dopamine hypothesis of schizophrenia: focus on the dopamine receptor

SH Snyder

Alleviation of schizophrenic symptoms by phenothiazines and butyrophenones is associated with blockade of dopamine receptors, while exacerbation of symptoms by amphetamines appears to result from enhanced synaptic activity of dopamine and/or norepinephrine. The author suggests that biochemical labeling of the dopamine receptor with 3H-dopamine and 3H-haloperidol may clarify mechanisms of drug effects on the dopamine receptor.


This article has been cited by other articles:


Home page
J. Neurosci.Home page
F. Errico, S. Rossi, F. Napolitano, V. Catuogno, E. Topo, G. Fisone, A. D'Aniello, D. Centonze, and A. Usiello
D-Aspartate Prevents Corticostriatal Long-Term Depression and Attenuates Schizophrenia-Like Symptoms Induced by Amphetamine and MK-801
J. Neurosci., October 8, 2008; 28(41): 10404 - 10414.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. R. Gardell, K. E. Vanover, L. Pounds, R. W. Johnson, R. Barido, G. T. Anderson, I. Veinbergs, A. Dyssegaard, P. Brunmark, A. Tabatabaei, et al.
ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 862 - 870.
[Abstract] [Full Text] [PDF]


Home page
Schizophr BullHome page
S. R. Laviolette
Dopamine Modulation of Emotional Processing in Cortical and Subcortical Neural Circuits: Evidence for a Final Common Pathway in Schizophrenia?
Schizophr Bull, July 1, 2007; 33(4): 971 - 981.
[Abstract] [Full Text] [PDF]


Home page
NeuroscientistHome page
U. Meyer, B. K. Yee, and J. Feldon
The Neurodevelopmental Impact of Prenatal Infections at Different Times of Pregnancy: The Earlier the Worse?
Neuroscientist, June 1, 2007; 13(3): 241 - 256.
[Abstract] [PDF]


Home page
J. Neurosci.Home page
J.-M. Beaulieu, E. Tirotta, T. D. Sotnikova, B. Masri, A. Salahpour, R. R. Gainetdinov, E. Borrelli, and M. G. Caron
Regulation of Akt Signaling by D2 and D3 Dopamine Receptors In Vivo
J. Neurosci., January 24, 2007; 27(4): 881 - 885.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. E. Vanover, D. M. Weiner, M. Makhay, I. Veinbergs, L. R. Gardell, J. Lameh, A. L. Del Tredici, F. Piu, H. H. Schiffer, T. R. Ott, et al.
Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 910 - 918.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. E. Vanover, S. C. Harvey, T. Son, S. R. Bradley, H. Kold, M. Makhay, I. Veinbergs, T. A. Spalding, D. M. Weiner, C. M. Andersson, et al.
Pharmacological Characterization of AC-90179 [2-(4-Methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 943 - 951.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. R. Sanders and P. V. Gejman
Influential Ideas and Experimental Progress in Schizophrenia Genetics Research
JAMA, June 13, 2001; 285(22): 2831 - 2833.
[Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
A. Cravchik and D. Goldman
Neurochemical Individuality: Genetic Diversity Among Human Dopamine and Serotonin Receptors and Transporters
Arch Gen Psychiatry, December 1, 2000; 57(12): 1105 - 1114.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. S. Lidow and P. S. Goldman-Rakic
Differential Regulation of D2 and D4 Dopamine Receptor mRNAs in the Primate Cerebral Cortex vs. Neostriatum: Effects of Chronic Treatment with Typical and Atypical Antipsychotic Drugs
J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 939 - 946.
[Abstract] [Full Text]


Home page
Journal of Research in NursingHome page
J. Stirling
Progress in research into the neurobiological bases of schizophrenia: A review and commentary
Journal of Research in Nursing, January 1, 1997; 2(6): 434 - 440.
[Abstract] [PDF]


Home page
ScienceHome page
S. Johnson, V Seutin, and R. North
Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump
Science, October 23, 1992; 258(5082): 665 - 667.
[Abstract] [PDF]


Home page
ScienceHome page
N. Andreasen
Brain imaging: applications in psychiatry
Science, March 18, 1988; 239(4846): 1381 - 1388.
[Abstract] [PDF]


Home page
ScienceHome page
D Pickar, R Labarca, M Linnoila, A Roy, D Hommer, D Everett, and S. Paul
Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients
Science, August 31, 1984; 225(4665): 954 - 957.
[Abstract] [PDF]


Home page
ScienceHome page
F. White and R. Wang
Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons
Science, September 9, 1983; 221(4615): 1054 - 1057.
[Abstract] [PDF]


Home page
ScienceHome page
D Lozovsky, C. Saller, and I. Kopin
Dopamine receptor binding is increased in diabetic rats
Science, November 27, 1981; 214(4524): 1031 - 1033.
[Abstract] [PDF]


Home page
ScienceHome page
J. Mann, M Stanley, S Gershon, and M Rossor
Mental symptoms in Huntington's disease and a possible primary aminergic neuron lesion
Science, December 19, 1980; 210(4476): 1369 - 1371.
[Abstract] [PDF]


Home page
ScienceHome page
S. Potkin, F Karoum, L. Chuang, H. Cannon-Spoor, I Phillips, and R. Wyatt
Phenylethylamine in paranoid chronic schizophrenia
Science, October 26, 1979; 206(4417): 470 - 471.
[Abstract] [PDF]


Home page
ScienceHome page
N. Bacopoulos, E. Spokes, E. Bird, and R. Roth
Antipsychotic drug action in schizophrenic patients: effect on cortical dopamine metabolism after long-term treatment
Science, September 28, 1979; 205(4413): 1405 - 1407.
[Abstract] [PDF]


Home page
ScienceHome page
J. Barchas, H Akil, G. Elliott, R. Holman, and S. Watson
Behavioral neurochemistry: neuroregulators and behavioral states
Science, May 26, 1978; 200(4344): 964 - 973.
[Abstract] [PDF]


Home page
ScienceHome page
P. Berger
Medical treatment of mental illness
Science, May 26, 1978; 200(4344): 974 - 981.
[Abstract] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 1976 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org